Lysosome inhibitor LLAD

Chemical Structure : Lysosome inhibitor LLAD

加入收藏

货号: PC-25859Not For Human Use, Lab Use Only.

LLAD is a long-term lysosome-targeting anticancer drug, inhibits SLC38A9 in lysosomes and alkalinizes lysosomes, induces apoptosis through long-term lysosomal damage in vivo and in vitro.

规格	价格	库存	数量
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote

获取报价单

* 请选择数量再加入购物车

or Bulk Inquiry

大包装，大折扣！

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

生物&药学活性

LLAD is a long-term lysosome-targeting anticancer drug, inhibits SLC38A9 in lysosomes and alkalinizes lysosomes, induces apoptosis through long-term lysosomal damage in vivo and in vitro.
LLAD exhibited a potent binding ability with SLC38A9 with SPR KD of 1.29 uM.
LLAD shows anti-proliferation activity with IC50 of 26.66 uM in A549 cells and 2.478 uM in HL-60 cells.
directly inhibit the activity of SLC38A9, inhibits mTOR signaling pathway and phosphorylation of mTOR and the substrates S6 kinase (S6K).
LLAD induces lysosomal damage (lysosomal stress response, LSR) by long-term retention.
LLAD (2.5 mg/kg) exhibited excellent long-term anticancer effect in HeLa xenograft mouse model.

物理化学性质&存储条件

分子量	401.47
分子式	C22H23N7O
外观性状	Solid
CAS No.
储存条件	固体粉末 -20°C 12 个月; 4°C 6 个月	配置液 -80°C 6 个月; -20°C 6 个月
Shipping
Solubility	10 mM in DMSO
Chemical Name/SMILES	N-(3-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)-1H-indazol-4-yl)acrylamide

参考文献

1. Zhao S, et al. Acta Pharm Sin B. 2025 Nov;15(11):5867-5879.